Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

Ray D. Page,Leylah Drusbosky,Hiba I. Dada,Victoria M. Raymond,Davey B. Daniel,Stephen G. Divers,Karen L. Reckamp,Miguel Angel Villalona-Calero,Justin I. Odegaard,Richard B. Lanman,Vassiliki A. Papadimitrakopoulou,Natasha B. Leighl

Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

2021

Ray D. Page
Leylah Drusbosky
Hiba I. Dada
Victoria M. Raymond
Davey B. Daniel
Stephen G. Divers
Karen L. Reckamp
Miguel Angel Villalona-Calero
Justin I. Odegaard
Richard B. Lanman
Vassiliki A. Papadimitrakopoulou
Natasha B. Leighl

9027Background: Somatic genomic testing is recommended by numerous expert guidelines to inform targeted therapy treatment for patients with advanced lung adenocarcinoma (aLUAD). The NILE study was ...

Keywords:

Targeted therapy
Adenocarcinoma
Oncology
Somatic cell
Medicine
Lung
Internal medicine
Personalized medicine
genomic profiling

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations